Literature DB >> 19130404

Canonical and non-canonical pathways of osteoclast formation.

H J Knowles1, N A Athanasou.   

Abstract

Physiological and pathological bone resorption is mediated by osteoclasts, multinucleated cells which are formed by the fusion of monocyte / macrophage precursors. The canonical pathway of osteoclast formation requires the presence of the receptor activator for NFkappaB ligand (RANKL) and macrophage colony stimulating factor (M-CSF). Non-canonical pathways of osteoclast formation have been described in which cytokines / growth factors can substitute for RANKL or M-CSF to induce osteoclast formation. Substitutes for RANKL include LIGHT, TNFalpha and interleukins 6, 11 and 8. M-CSF substitutes include vascular endothelial growth factor (VEGF), placental growth factor (PlGF), FLt-3 ligand and hepatocyte growth factor (HGF). These growth factors can also influence canonical (RANKL / M-CSF-induced) osteoclast formation. Both canonical and non-canonical pathways of osteoclast formation play a role in the formation of osteolytic lesions where there is increased osteoclast formation and activity, such as in giant cell tumour of bone.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19130404     DOI: 10.14670/HH-24.337

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  25 in total

Review 1.  New knowledge on critical osteoclast formation and activation pathways from study of rare genetic diseases of osteoclasts: focus on the RANK/RANKL axis.

Authors:  J C Crockett; D J Mellis; D I Scott; M H Helfrich
Journal:  Osteoporos Int       Date:  2010-05-11       Impact factor: 4.507

2.  Proteoglycans and osteolysis.

Authors:  Marc Baud'Huin; Céline Charrier; Gwenola Bougras; Régis Brion; Frédéric Lezot; Marc Padrines; Dominique Heymann
Journal:  Methods Mol Biol       Date:  2012

Review 3.  The osteoclast--what's new?

Authors:  Nicolas A Athanasou
Journal:  Skeletal Radiol       Date:  2011-08-17       Impact factor: 2.199

4.  Breast cancer at bone metastatic sites: recent discoveries and treatment targets.

Authors:  Osama Hussein; Svetlana V Komarova
Journal:  J Cell Commun Signal       Date:  2011-01-19       Impact factor: 5.782

5.  HIF-1α disturbs osteoblasts and osteoclasts coupling in bone remodeling by up-regulating OPG expression.

Authors:  Jin Shao; Yan Zhang; Tieyi Yang; Jin Qi; Lianfang Zhang; Lianfu Deng
Journal:  In Vitro Cell Dev Biol Anim       Date:  2015-04-10       Impact factor: 2.416

6.  Influences of IL-6R antibody on PMMA bone cement-mediated expression of OPG and RANKL in synovial fibroblasts.

Authors:  Ke Tao; Hui Zeng; De-Ming Xiao; Ao Xiong; Jian Weng; Bin Kang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-04-08

7.  Hyperglycemia induced and intrinsic alterations in type 2 diabetes-derived osteoclast function.

Authors:  D L Catalfamo; T M Britten; D L Storch; N L Calderon; H L Sorenson; S M Wallet
Journal:  Oral Dis       Date:  2013-04       Impact factor: 3.511

Review 8.  Non-Canonical (RANKL-Independent) Pathways of Osteoclast Differentiation and Their Role in Musculoskeletal Diseases.

Authors:  A Sabokbar; D J Mahoney; F Hemingway; N A Athanasou
Journal:  Clin Rev Allergy Immunol       Date:  2016-08       Impact factor: 8.667

9.  Hypoxia-inducible factor regulates osteoclast-mediated bone resorption: role of angiopoietin-like 4.

Authors:  Helen J Knowles; Anne-Marie Cleton-Jansen; Eberhard Korsching; Nicholas A Athanasou
Journal:  FASEB J       Date:  2010-07-28       Impact factor: 5.191

10.  Potential of delphinidin-3-rutinoside extracted from Solanum melongena L. as promoter of osteoblastic MC3T3-E1 function and antagonist of oxidative damage.

Authors:  Lavinia Casati; Francesca Pagani; Marta Fibiani; Roberto Lo Scalzo; Valeria Sibilia
Journal:  Eur J Nutr       Date:  2018-01-25       Impact factor: 5.614

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.